Welcome to LookChem.com Sign In|Join Free
  • or
2,5-Pyrrolidinedione, 1-(1-oxo-4-phenylbutoxy)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

88556-26-7

Post Buying Request

88556-26-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

88556-26-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 88556-26-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,5,5 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 88556-26:
(7*8)+(6*8)+(5*5)+(4*5)+(3*6)+(2*2)+(1*6)=177
177 % 10 = 7
So 88556-26-7 is a valid CAS Registry Number.

88556-26-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (2,5-dioxopyrrolidin-1-yl) 4-phenylbutanoate

1.2 Other means of identification

Product number -
Other names 4-Phenyl-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:88556-26-7 SDS

88556-26-7Relevant academic research and scientific papers

"clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals

Bachmann, Michael,Brandt, Florian,Kopka, Klaus,Laube, Markus,Pietzsch, Jens,Ullrich, Martin,Wodtke, Robert,L?ser, Reik,Pietzsch, Hans-Jürgen,Van Den Hoff, J?rg

supporting information, p. 710 - 733 (2022/01/11)

The intentional binding of radioligands to albumin gains increasing attention in the context of radiopharmaceutical cancer therapy as it can lead to an enhanced radioactivity uptake into the tumor lesions and, thus, to a potentially improved therapeutic outcome. However, the influence of the radioligand's albumin-binding affinity on the time profile of tumor uptake has been only partly addressed so far. Based on the previously identified N?-4-(4-iodophenyl)butanoyl-lysine scaffold, we designed "clickable"lysine-derived albumin binders (cLABs) and determined their dissociation constants toward albumin by novel assay methods. Structure-activity relationships were derived, and selected cLABs were applied for the modification of the somatostatin receptor subtype 2 ligand (Tyr3)octreotate. These novel conjugates were radiolabeled with copper-64 and subjected to a detailed in vitro and in vivo radiopharmacological characterization. Overall, the results of this study provide an incentive for further investigations of albumin binders for applications in endoradionuclide therapies.

Comparison of the inhibition of human and Trypanosoma cruzi prolyl endopeptidases

Vendeville, Sandrine,Goossens, Filip,Debreu-Fontaine, Marie-Ange,Landry, Valérie,Davioud-Charvet, Elisabeth,Grellier, Philippe,Scharpe, Simon,Sergheraert, Christian

, p. 1719 - 1729 (2007/10/03)

Prolyl endopeptidases (PEPs) have been found in numerous species. Inhibitors of human enzyme could correct cognitive deficits in Alzheimer patients while inhibition of Trypanosoma cruzi PEP could prevent invasion phase in Chagas disease. A structure-activity relationship study carried out in a tetrahydroisoquinoline series allowed to obtain potent competitive inhibitors superior to SUAM-1221. Besides, inhibitors expected to act according to an irreversible mechanism revealed to be superior to JPT-4819, for applications linked to human enzyme inhibition.

Development of Potent and Selective CCK-A Receptor Agonists from Boc-CCK-4: Tetrapeptides Containing Lys(Nε)-Amide Residues

Shiosaki, Kazumi,Lin, Chun Wel,Kopecka, Hana,Craig, Richard A.,Bianchi, Bruce R.,et al.

, p. 2007 - 2014 (2007/10/02)

A series of Boc-CCK-4 derivatives represented by the general structure Boc-Trp-Lys(Nε-COR)-Asp-Phe-NH2, where R is an aromatic, heterocyclic, or aliphatic group, are potent and selective CCK-A receptor agonists.These amide-bearing compounds complement the previously described urea-based tetrapeptides (Shiosaki et al.J.Med.Chem. 1991,34,2837-2842); structure-activity studies revealed parallel as well as divergent trends between these two series.A significant correlation was observed between pancreatic binding affinity and the resonance constant R of the phenyl substituent in one particular series of derivatives.Sulfation of phenolic amides appended onto the ε-amino group of the lysine did not affect affinity for the CCK-A receptor in contrast to the 500-fold increase in binding potency observed upon sulfation of CCK-8, suggesting that the lysine appendage and the sulfated tyrosine in CCK-8, both key structural elements that impart high affinity for the CCK-A receptor, are interacting differently with the receptor.The amide-bearing tetrapeptides are full agonists relative to CCK-8 in stimulating pancreatic amylase release while being partial agonists in eliciting phosphoinositide (PI) hydrolysis.Both effects were blocked by selective CCK-A receptor antagonists

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 88556-26-7